DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tasisulam is an investigational drug.
There have been 11 clinical trials for Tasisulam. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Melanoma, Fallopian Tube Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
There are six US patents protecting this investigational drug and fifty-four international patents.
Recent Clinical Trials for Tasisulam
|A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients||Eli Lilly and Company||Phase 1|
|A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma||Eli Lilly and Company||Phase 1|
|A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma||Eli Lilly and Company||Phase 3|
Top disease conditions for Tasisulam
Top clinical trial sponsors for Tasisulam
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tasisulam||Start Trial||Thiophene-amd thiazolesulfonamides as antineoplastic agents||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|Tasisulam||Start Trial||Thiophene-and thiazolesulfonamides as antineoplastic agents||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|Tasisulam||Start Trial||TGF-beta receptor inhibitors to enhance direct reprogramming||The General Hospital Corporation (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|